Progenics Pharmaceuticals, Inc. clinical trials
Acquired by Lantheus Holdings, Inc., Jun 19, 2020 · source ↗
The registry lists 8 studies whose lead sponsor is Progenics Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2025.
Before and after it joined Lantheus Holdings, Inc.
- First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- 8
- First submitted after Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Progenics Pharmaceuticals, Inc.8 studies
Something wrong with this grouping? Tell us on the Lantheus Holdings, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Lantheus Holdings, Inc. studies →
- I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).CompletedNCT03939689Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT01695044Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- An Open-label Extension Study of PSMA ADC 2301 in mCRPCCompletedNCT02020135Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414296Phase 1
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414283Phase 1
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.
- Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected PatientsCompletedNCT00055185Phase 2
Sponsor listed in the registry: Progenics Pharmaceuticals, Inc. · First submitted before Progenics Pharmaceuticals, Inc. became part of Lantheus Holdings, Inc.